ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

The study is set to be completed in January of 2021, following 12-months dosing.

“We have found this innovative, minimally invasive device to be a safe and effective option for lumbar interbody fusion procedures,” said SCOUT lead investigator John Chi, M.D., M.P.H. Dr. Chi is the Director of Neurosurgical Oncology at Brigham and Women’s Hospital in Boston, Massachusetts, and Associate Professor of Neurosurgery at Harvard Medical School, and the author of the SPINE article.

“The clinical results of STOP AF First demonstrate the superiority of Medtronic cryoablation as a first-line treatment for AF patients, before the disease progresses,” said Dr. Oussama Wazni, principal investigator for the STOP AF First trial and section head of electrophysiology at the Cleveland Clinic.

DETOUR1 Clinical Trial includes a 79% primary patency, with 82% of patients maintaining freedom from major adverse events at 2 years post-procedure.

Append Medical notes the procedures were completed with IMMR, one of the world’s leading preclinical laboratories and paves the way for the first human trial.